Clinical Trials Logo
  1. Home
  2. MDS
  3. NCT05009537
  4. Details
NCT05009537 Clinical Trial

Optical Genome Mapping in Hematological Malignancies

MDS Clinical Trial

— CARTOGEN  

Official title:
Optical Genome Mapping in Hematological Malignancies

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05009537
Other study ID # CARTOGEN - 29BRC21.0211
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date September 2021
Est. completion date September 2026

Study information
Verified date August 2021
Source University Hospital, Brest
Contact Marie-Bérengère, TROADEC, PhD
Phone (33)230338055
Email Marie-berengere.troadec@chu-brest.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer

Recruitment information / eligibility
Status Recruiting
Enrollment 200
Est. completion date September 2026
Est. primary completion date September 2022
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Minor/Major Patients - Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made. - No objection made or consent given Exclusion Criteria: - Patients under judicial protection (guardianship, curatorship, ...), - Refusal to participate

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France CHRU de Brest Brest
France CH Morlaix, service d'hémato clinique Morlaix
France CHIC, service d'hémato clinique Quimper
France CH St Brieuc, service d'hémato clinique Saint-Brieuc

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer identification of anomalies by mapping identical to those identified by combining conventional cytogenetics and FISH. 2021-2026
Secondary identification of new chromosomal abnormalities of clinical relevance. 2021-2026
Secondary identification of new chromosomal anomalies involved in oncogenic pathways 2021-2026
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04623944 - NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS Phase 1
Recruiting NCT03680677 - Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Not yet recruiting NCT04110925 - Mutational Analysis as a Prognostic and Predictive Marker of Cardiovascular (CVD) Disease in Patients With Myelodysplasia N/A
Terminated NCT04638309 - APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) Phase 1
Completed NCT03466320 - DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 Phase 1/Phase 2
Withdrawn NCT03138395 - iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML N/A
Completed NCT04443751 - A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Phase 1
Completed NCT02103478 - Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS) Phase 1/Phase 2
Completed NCT00863148 - Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL) Phase 2
Completed NCT00761449 - Lenalidomide in High-risk MDS and AML With Del(5q) or Monosomy 5 Phase 2
Completed NCT00692926 - Unrelated Umbilical Cord Blood Transplantation Augmented With ALDHbr Umbilical Cord Blood Cells Phase 1
Terminated NCT00176930 - Stem Cell Transplant for Hematological Malignancy N/A
Completed NCT02214407 - Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML Phase 3
Recruiting NCT05582902 - Study Investigating Patient-Reported Outcomes in Lower-risk MDS Patients
Not yet recruiting NCT05024877 - Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia Phase 2/Phase 3
Completed NCT00321711 - Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents Phase 2
Recruiting NCT06156579 - Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML Phase 2
Recruiting NCT05226455 - Venetoclax in Patients With MDS or AML in Relapse After AHSCT Phase 1/Phase 2
Completed NCT01690507 - Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML） Phase 1/Phase 2
Completed NCT01241500 - Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts Phase 3